PD-1-based combination therapy versus monotherapy in relapsed or refractory classical Hodgkin lymphoma: a single-center retrospective cohort study
Abstract
BackgroundProgrammed cell death 1 (PD-1) inhibitors are active in relapsed or refractory classical Hodgkin lymphoma (R/R cHL), but evidence directly comparing combination therapy with monotherapy in routine practice is limited.MethodsThis single-center retrospective cohort included 123 consecutive patients treated from 2019 through 2025 with PD-1-based combination therapy (n=98) or PD-1 monotherapy (n=25). Responses were assessed using Lugano 2014 criteria. Progression-free survival (PFS) counted progression or death as events. Kaplan-Meier, baseline-only Cox regression, and overlap-weighted propensity score analyses were used. Response endpoints were additionally analyzed with multivariable and overlap-weighted logistic regression, and the robustness of the PFS association was examined in a sensitivity series and with E-values.ResultsTreatment groups differed substantially at baseline; monotherapy recipients were older and had worse performance status. Unadjusted complete response (CR) was higher with combination therapy (65/98, 66.3% vs 9/25, 36.0%; P = 0.011), but this difference was attenuated and no longer significant after adjustment (overlap-weighted odds ratio [OR] 1.91; 95% CI, 0.67-5.45). The objective response advantage persisted (87/98, 88.8% vs 15/25, 60.0%; overlap-weighted OR 4.57; 95% CI, 1.36-15.43). With 45 PFS events, the unadjusted HR for combination therapy versus monotherapy was 0.27 (95% CI, 0.15-0.49); the baseline-adjusted HR was 0.44 (95% CI, 0.21-0.89). The overlap-weighted HR was 0.45 (95% CI, 0.23-0.91). The PFS association was stable across an extended sensitivity series (HR range, 0.40-0.48) and among the 95 patients who did not undergo consolidative autologous stem cell transplantation (adjusted HR 0.42; 95% CI, 0.20-0.89). Grade 3–4 neutropenia occurred in 27/98 (27.6%) combination-treated patients and 1/25 (4.0%) monotherapy-treated patients. Regimen subgroup analyses did not establish efficacy equivalence. Across eight prespecified maximum-grade safety fields, at least one recorded grade >=3 event occurred in 20/35 (57.1%) with PD-1+GVD, 5/32 (15.6%) with PD-1+brentuximab vedotin and 8/31 (25.8%) with PD-1+bendamustine (P = 0.001).ConclusionsPD-1-based combination therapy was associated with a higher objective response rate and longer PFS than monotherapy, whereas the complete response difference did not persist after adjustment. The retrospective design, small monotherapy group, and potential unmeasured confounding mean that further research is needed to confirm this conclusion.
Related
- Total marrow and lymphoid irradiation in combination with cyclophosphamide and etoposide before haematopoietic cell transplantation for relapsed or refractory acute leukaemia: a single-centre, open-label, phase 2 trial
- Real-world outcomes of glofitamab monotherapy in heavily pretreated patients with relapsed/refractory diffuse large B-cell lymphoma: A multicenter Korean cohort.
- On closing the gap: anti-PD-1-based salvage in relapsed/ refractory classical Hodgkin lymphoma. Comment on: “Mind the gap: anti-PD-1 salvage before autologous transplantation in classical Hodgkin lymphoma”
- Comparative effectiveness of first-/second-generation EGFR-TKI combination therapy versus third-generation EGFR-TKI monotherapy in untreated locally advanced or metastatic EGFR-mutant NSCLC: a real-world, retrospective study in China
- Infectious Complications and Toxicities of the Teclistamab Plus Daratumumab Combination in Relapsed or Refractory Multiple Myeloma: A Disproportionality and Drug–Interaction Analysis of the FDA Adverse Event Reporting System
BibTeX
@article{zhang2026pd1based,
title = {{PD-1-based combination therapy versus monotherapy in relapsed or refractory classical Hodgkin lymphoma: a single-center retrospective cohort study}},
author = {Weiming Zhang and Nasha Yu and Qiang Ding and Xiangxiang Song and Pingping Yu and Xing Zhong},
journal = {Frontiers in Oncology},
year = {2026},
month = nov,
doi = {10.3389/fonc.2026.1934193},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1934193},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - PD-1-based combination therapy versus monotherapy in relapsed or refractory classical Hodgkin lymphoma: a single-center retrospective cohort study
AU - Weiming Zhang
AU - Nasha Yu
AU - Qiang Ding
AU - Xiangxiang Song
AU - Pingping Yu
AU - Xing Zhong
PY - 2026
DA - 2026/11/04
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1934193
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.1934193
AB - BackgroundProgrammed cell death 1 (PD-1) inhibitors are active in relapsed or refractory classical Hodgkin lymphoma (R/R cHL), but evidence directly comparing combination therapy with monotherapy in routine practice is limited.MethodsThis single-center retrospective cohort included 123 consecutive patients treated from 2019 through 2025 with PD-1-based combination therapy (n=98) or PD-1 monotherapy (n=25). Responses were assessed using Lugano 2014 criteria. Progression-free survival (PFS) counted progression or death as events. Kaplan-Meier, baseline-only Cox regression, and overlap-weighted propensity score analyses were used. Response endpoints were additionally analyzed with multivariable and overlap-weighted logistic regression, and the robustness of the PFS association was examined in a sensitivity series and with E-values.ResultsTreatment groups differed substantially at baseline; monotherapy recipients were older and had worse performance status. Unadjusted complete response (CR) was higher with combination therapy (65/98, 66.3% vs 9/25, 36.0%; P = 0.011), but this difference was attenuated and no longer significant after adjustment (overlap-weighted odds ratio [OR] 1.91; 95% CI, 0.67-5.45). The objective response advantage persisted (87/98, 88.8% vs 15/25, 60.0%; overlap-weighted OR 4.57; 95% CI, 1.36-15.43). With 45 PFS events, the unadjusted HR for combination therapy versus monotherapy was 0.27 (95% CI, 0.15-0.49); the baseline-adjusted HR was 0.44 (95% CI, 0.21-0.89). The overlap-weighted HR was 0.45 (95% CI, 0.23-0.91). The PFS association was stable across an extended sensitivity series (HR range, 0.40-0.48) and among the 95 patients who did not undergo consolidative autologous stem cell transplantation (adjusted HR 0.42; 95% CI, 0.20-0.89). Grade 3–4 neutropenia occurred in 27/98 (27.6%) combination-treated patients and 1/25 (4.0%) monotherapy-treated patients. Regimen subgroup analyses did not establish efficacy equivalence. Across eight prespecified maximum-grade safety fields, at least one recorded grade >=3 event occurred in 20/35 (57.1%) with PD-1+GVD, 5/32 (15.6%) with PD-1+brentuximab vedotin and 8/31 (25.8%) with PD-1+bendamustine (P = 0.001).ConclusionsPD-1-based combination therapy was associated with a higher objective response rate and longer PFS than monotherapy, whereas the complete response difference did not persist after adjustment. The retrospective design, small monotherapy group, and potential unmeasured confounding mean that further research is needed to confirm this conclusion.
SN - 2234-943X
ER -